Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel
Maciej Banach, Manfredi Rizzo, Peter P Toth, Michel Farnier, Michael H Davidson, Khalid Al-Rasadi, Wilbert S Aronow, Vasilis Athyros, Dragan M Djuric, Marat V Ezhov, Robert S Greenfield, G Kees Hovingh
(+19 others)
2015
Expert Opinion on Drug Safety
A b s t r a c t Statins are one of the most commonly prescribed drugs in clinical practice. They are usually well tolerated and effectively prevent cardiovascular events. Most adverse effects associated with statin therapy are musclerelated. The recent statement of the European Atherosclerosis Society (EAS) has focused on statin associated muscle symptoms (SAMS), and avoided the use of the term 'statin intolerance'. Although muscle syndromes are the most common adverse effects observed after
more »
... tin therapy, excluding other side effects might underestimate the number of patients with statin intolerance, which might be observed in 10-15% of patients. In clinical practice, statin intolerance limits effective treatment of patients at risk of, or with, cardiovascular disease. Knowledge of the most common adverse effects of statin therapy that might cause statin intolerance and the clear definition of this phenomenon is crucial to effectively treat patients with lipid disorders. Therefore, the aim of this position paper was to suggest a unified definition of statin intolerance, and to complement the recent EAS statement on SAMS, where the pathophysiology, diagnosis and the management were comprehensively presented. Statin intolerance -an attempt at a unified definition. Position paper from an International Lipid Expert Panel Arch Med Sci 1, February / 2015 ↑ Constipation, diarrhea, dyspepsia, flatulence heartburn, nausea vomiting [43] Hepatic < 1.5% hepatotoxicity in coronary artery disease patients in 5 years [1] ↑ Activity of liver enzymes [27, 28] Skin ↑ Risk of alopecia [52], lichenoid eruption [53], dermographism [54], chronic urticaria [55], toxic epidermal necrolysis [56] and rash by 1-4% [57] Eye ↑ The risk of cataract by 27% [58] ↑ Diplopia, ptosis and ophthalmoplegia [59] Renal ↑ Risk of acute renal failure [60], ↑ proteinuria [61] Reproductive Erectile dysfunction [62], decrease libido [63], gynecomastia [64], ↓ testosterone levels by 10.3% and by 7.5% respectively after 48 weeks of statins [65] Blood ↑ Risk of thrombotic thrombocytopenic purpura (TPP) [66-68]
doi:10.1517/14740338.2015.1039980
pmid:25907232
fatcat:n2spltfkpfg6ppdyiidcxmivuq
